参考文献/References:
[1]Borissoff JI,Joosen IA,Versteylen MO,et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state[J]. Arterioscler Thromb Vasc Biol,2013,33(8):2032-2040.
[2]Gimbrone MA Jr,García-Carde?a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis[J]. Circ Res,2016,118(4):620-636.
[3]Ramji DP,Davies TS. Cytokines in atherosclerosis:key players in all stages of disease and promising therapeutic targets[J]. Cytokine Growth Factor Rev,2015,26(6):673-685.
[4]Edfeldt K,Agerberth B,Rottenberg ME,et al. Involvement of theantimicrobial peptide LL-37 in human a therosclerosis[J]. Arterioscler Thromb Vasc Biol,2006,26(7):1551-1557．
[5]D?ring Y,Drechsler M,Wantha S,et al. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice[J]. Circ Res,2012,110(8):1052-1056.
[6]Carbone F,Mach F,Montecucco F. Update on the role of neutrophils in atherosclerotic plaque vulnerability[J]. Curr Drug Targets,2015,16(4):321-333.
[7]Pende A,Artom N,Bertolotto M,et al. Role of neutrophils in atherogenesis:an update[J]. Eur J Clin Invest,2016,46(3):252-263.
[8]Pugliese G,Iacobini C,Blasetti Fantauzzi C,et al. The dark and bright side of atherosclerotic calcification[J]. Atherosclerosis,2015,238(2):220-230.
[9]Chistiakov DA,Orekhov AN,Bobryshev YV. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability[J]. Acta Physiol (Oxf),2015,213(3):539-553.
[10]Ionita MG,van den Borne P,Catanzariti LM,et al. High neutrophil numbers in human carotidatherosclerotic plaques are associated with characteristics of rupture-prone lesions[J]. Arterioscler Thromb Vasc Biol,2010,30(9):1842-1848.
[11]Driscoll WS,Vaisar T,Tang JJ,et al. Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype[J]. CircＲes,2013,113(1):52-61.
[12]Hartwig H,Silvestre Roig C,Daemen M,et al. Neutrophils in atherosclerosis. A brief overview[J]. Hamostaseologie,2015,35(2):121-127.
[13]Silvestre-Roig C,Braster Q,Wichapong K,et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death[J]. Nature,2019,569(7755):236-240.
[14]D?ring Y,Manthey HD,Drechsler M,et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis[J]. Circulation,2012,125(13):1673-1683．
[15]Goossens P,Gijbels MJJ,Zernecke A,et al. Myeloid type I interferon signaling promotesatherosclerosis by stimulating macrophage recruitment to lesions[J]. Cell Metab,2010,12(2):142-153.
[16]Knight JS,Luo W,O’Dell AA,et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosderosis[J]. Cire Res,2014,114(6):947-956.
[17]Kojima Y,Weissman IL,Leeper NJ. The role of efferocytosis in atherosclerosis[J]. Circulation,2017,135(5):476-489.
[18]Jia HB,Abtahian F,Aguirre AD,et al. In vivo diagnosis of plaque erosion and calcifiednodule in patients with acute coronary syndrome by intravascular optical coherence tomography[J]. J Am Coll Cardiol,2013,62(19):1748-1758.
[19]Quillard T,Araújo HA,Franck G,et al. Editor’s choice:TLR2 and neutrophils potentiate endothelial stress,apoptosis and detachment:implications for superficial erosion[J]. Eur HeartJ,2015,36(22):1394-1404.
[20]Mangold A,Alias S,Scherz T,et al. Coronary neutrophil extracellular trap burden and dnase activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size[J]. Circ Res,2015,116(7):1182-1192．
[21]Ge L,Zhou X,Ji WJ,et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow:therapeutic potential of DNase-based reperfusion strategy[J]. Am J Physiol Heart Circ Physiol,2015,308(5):H500-H509.
[22]Riegger J,Byrne RA,Joner M,et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study:a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium[J]. Eur Heart J,2016,37(19):1538-1549.
[23]Fuchs TA,Brill A,Duerschmied D,et al. Extracellular DNA traps promote thrombosis[J]. Proc Natl Acad Sci U S A,2010,107(36):15880-15885.
[24]Wang YB,Liu XY,Xia PP,et al. The regulatory role of microRNAs on phagocytes:a potential therapeutic target for chronic diseases[J]. Front Immunol,2022,13:901166-901185.
[25]Warnatsch A,Ioannou M,Wang Q,et al. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis[J]. Science,2015,349(6245):316-320.
[26]Pertiwi KR,van der Wal AC,Pabittei DR,et al. Neutrophil extracellular traps participate in alldifferent types of thrombotic and haemorrhagic complications of coronary atherosclerosis[J]. Thromb Haemost,2018,118(6):1078-1087.
[27]Dai JN,Xing L,Jia HB,et al. In vivo predictors of plaque erosion in patients with ST-segment elevation myocardial infarction:a clinical, angiographical, and intravascular optical coherence tomography study[J]. Eur Heart J,2018,39(22):2077-2085.
[28]Wang QZ,Zhao H,Qi N,et al. Generation and stability of size-adjustable bulk nanobubbles based on periodic pressure change[J]. Sci Rep,2019,9(1):1118-1126.
[29]Langseth MS,Opstad TB,Bratseth V,et al. Markers of neutrophil extracellular traps are associated with adverse clinical outcome in stable coronary artery disease[J]. Eur J Prev Cardiol,2018,25(7):762-769.
[30]Liu CQ,Desikan R,Ying ZK,et al. Effects of a novel pharmacologic inhibitor of myeloperoxidase in a mouse atherosclerosis model[J]. PLoS One,2012,7(12):e50767-e50777.
[31]Ali M,Pulli B,Courties G,et al. Myeloperoxidase inhibition improves ventricular function and remodeling after experimental myocardial infarction[J]. JACC Basic Transl Sci,2016,1(7):633-643.
[32]Fukuta T,Okada H,Takemura G,et al. Neutrophil elastase inhibition ameliorates endotoxin-induced myocardial injury accompanying degradation of cardiac capillary glycocalyx[J]. Shock,2020,54(3):386-393.
[33]Bidouard JP,Duval N,Kapui Z,et al. SSR69071,an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury[J]. Eur J Pharmacol,2003,461(1):49-52.
[34]Schumski A,Ortega-Gómez A,Wichapong K,et al. Endotoxinemia Accelerates Atherosclerosis through Electrostatic Charge-Mediated Monocyte Adhesion[J]. Circulation,2021,143(3):254-266.
[35]Connolly SJ,Eikelboom JW,Bosch J,et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease:an international,randomised,double-blind,placebo-controlledtrial[J].Lancet,2018,391(10117):205-218.
[36]Healy LD,Puy C,Itakura A,et al. Colocalization of neutrophils,extracellular DNA and coagulation factors during NETosis:development and utility of an immunofluorescence-basemicroscopy platform[J]. J Immunol Methods,2016,435:77-84.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(12):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(12):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(12):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(12):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(12):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(12):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]